Yang J, Peng H, Tu SK, Li M, Song K. Extramedullary plasmacytoma with the uvula as first affected site: A case report. World J Clin Oncol 2025; 16(1): 96131 [DOI: 10.5306/wjco.v16.i1.96131]
Corresponding Author of This Article
Kui Song, MD, Chief Doctor, Department of Hematology, The First Affiliated Hospital of Jishou University, 26 Century Avenue, Qianzhou, Jishou 416000, Hunan Province, China. js_hematology@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jan 24, 2025; 16(1): 96131 Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.96131
Extramedullary plasmacytoma with the uvula as first affected site: A case report
Jing Yang, Hui Peng, Sheng-Ke Tu, Min Li, Kui Song
Jing Yang, Hui Peng, Sheng-Ke Tu, Kui Song, Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Min Li, Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China
Author contributions: Yang J, Tu SK, Li M, Peng H, and Song K conceived and designed the study, collected and interpreted all the relevant clinical and laboratory data, and prepared the manuscript; all authors read and approved the final manuscript; JY, Tu SK, Li M, Peng H, and Song K confirm the authenticity of all the raw data in this study.
Supported byHunan Innovative Province Construction Special Task Book, No. 2021SK4050; and Innovation Platform and Talent Program of Hunan Province, No. 2023JJ30609.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and the accompanying images.
Conflict-of-interest statement: All authors declare that they have no competing interests to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kui Song, MD, Chief Doctor, Department of Hematology, The First Affiliated Hospital of Jishou University, 26 Century Avenue, Qianzhou, Jishou 416000, Hunan Province, China. js_hematology@163.com
Received: April 27, 2024 Revised: September 3, 2024 Accepted: September 23, 2024 Published online: January 24, 2025 Processing time: 185 Days and 18.1 Hours
Core Tip
Core Tip: The high-risk characteristics of extramedullary plasmacytoma in clinical manifestations stem from its pathogenesis and the high-risk trait of cytogenetics. There are limited recommendations and guidelines for this type of tumor owing to the rarity of extramedullary plasmacytoma (EMP) of the uvula. Radiotherapy is the preferred treatment after diagnosis. Chemotherapy is ideal for cases with multiple recurrence, extensive local invasion, and poor histological differentiation. The current chemotherapy regimen can refer to the chemotherapy regimen for multiple myeloma. We report a rare case of EMP with the uvula as the first affected site; therefore, the relevant literature is reviewed to enhance clinicians' awareness of such rare comorbidities.